Cover Image
市場調查報告書

標的藥物遞送相關的聯盟趨勢:條件、契約內容

Global Targeted Drug Delivery Partnering 2010-2016

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 309770
出版日期 內容資訊 英文 170 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
標的藥物遞送相關的聯盟趨勢:條件、契約內容 Global Targeted Drug Delivery Partnering 2010-2016
出版日期: 2016年11月18日 內容資訊: 英文 170 Pages
簡介

本報告提供全球標的藥物遞送相關的企業聯盟(夥伴關係)的締結趨勢與其內容(聯盟條件)相關分析,近幾年的企業聯盟趨勢和特徵(各契約方式、各開發階段、各治療領域等),平均交易條件,代表性交易案例,大型製藥企業的契約動向,近幾年的聯盟交易一覽與其明細等資訊彙整,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 標的藥物遞送相關的企業聯盟的締結趨勢

  • 簡介
  • 近幾年的標的藥物遞送相關的聯盟趨勢
  • 大型製藥企業之標的藥物遞送相關的聯盟活動
  • 標的藥物遞送相關的聯盟:契約的各類型
  • 標的藥物遞送相關的聯盟:各治療領域
  • 公開的資本交易的條件
    • 付款總額
    • 預付款金
    • 階段性付款
    • 權利金比率

第3章 標的藥物遞送相關的代表性資本交易

  • 簡介
  • 與標的藥物遞送相關的代表性資本交易交易金額

第4章 大型製藥企業之標的藥物遞送相關的聯盟活動

  • 簡介
  • 大型製藥企業之標的藥物遞送相關的聯盟活動
  • 標的藥物遞送相關的大聯盟企業簡介

第5章 標的藥物遞送相關的交易形成一覽

  • 簡介
  • 交易形成的一覽

第6章 標的藥物遞送相關交易形成:各技術類型

第7章 聯盟資源中心

  • 線上聯盟
  • 聯盟趨勢
  • 相關資料

附錄

  • 附錄1:企業名順序(A∼Z)
  • 附錄2:各臨床實驗階段
    • 藥物研發
    • 前臨床
    • 第一階段
    • 第二階段
    • 第三階段
    • 認證中
    • 已上市
    • 處方(製劑)設計
  • 附錄3:各交易類型
    • 資產購買
    • 大型製藥企業的轉出授權
    • 共同開發
    • 共同研究開發(R&D)
    • 共同販賣
    • 共同促銷
    • 共同研究開發協定(CRADA)
    • 交叉許可
    • 開發
    • 流通
    • 股票購買
    • 評估
    • 津貼
    • 合資企業
    • 許可證
    • 訴訟
    • 製造
    • 行銷
    • 物質移動
    • 選擇
    • 推銷
    • 研究
    • 調停
    • 衍生公司
    • 再授權
    • 供給
    • 技術移交
    • 契約結束
    • 保證
  • 附錄4:各治療領域
  • 附錄5:交易種類定義

關於Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Current Partnering 最新報告

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2102tar

Targeted Drug Delivery Partnering 2010-2016 report provides understanding and access to the targeted drug delivery partnering deals and agreements entered into by the world's leading healthcare companies.

  • Trends in targeted drug delivery partnering deals
  • Top targeted drug delivery deals by value
  • Deals listed by company A-Z, deal type, stage of development, therapy type

This report provides details of the latest Targeted Drug Delivery agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Targeted Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Targeted Drug Delivery partnering deals.

The report presents financial deal term values for Targeted Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Targeted Drug Delivery partnering field; both the leading deal values and most active Targeted Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 160 online deal records of actual Targeted Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Targeted Drug Delivery dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Targeted Drug Delivery dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Targeted Drug Delivery deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Targeted Drug Delivery dealmaking with a brief summary followed by a comprehensive listing of Targeted Drug Delivery deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Targeted Drug Delivery partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Targeted Drug Delivery partnering deals signed and announced since Jan 2010. The chapter is organized by specific Targeted Drug Delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Targeted Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Targeted Drug Delivery partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Targeted Drug Delivery technologies and products.

Key benefits

Global Targeted Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

  • In-depth understanding of Targeted Drug Delivery deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Targeted Drug Delivery agreements with numerous real life case studies
  • Detailed access to actual Targeted Drug Delivery contracts entered into by leading biopharma companies
  • Identify most active Targeted Drug Delivery dealmakers since 2010
  • Insight into terms included in a Targeted Drug Delivery partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Targeted Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Targeted Drug Delivery trends and structure of deals entered into by leading companies worldwide.

Targeted Drug Delivery Partnering Terms and Agreements includes:

  • Trends in Targeted Drug Delivery dealmaking in the biopharma industry since 2010
  • Analysis of Targeted Drug Delivery deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Targeted Drug Delivery deals
  • Access to Targeted Drug Delivery contract documents
  • Leading Targeted Drug Delivery deals by value since 2010
  • Most active Targeted Drug Delivery dealmakers since 2010

In Global Targeted Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Targeted Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 160 Targeted Drug Delivery deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Targeted Drug Delivery Partnering 2010-2016 report provides the reader with the following key benefits:

  • In-depth understanding of Targeted Drug Delivery deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Targeted Drug Delivery agreements with numerous real life case studies
  • Detailed access to actual Targeted Drug Delivery contracts entered into by leading biopharma companies
  • Identify most active Targeted Drug Delivery dealmakers since 2010
  • Insight into terms included in a Targeted Drug Delivery partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Targeted Drug Delivery dealmaking

  • 2.1. Introduction
  • 2.2. Targeted Drug Delivery partnering over the years
  • 2.3. Most active Targeted Drug Delivery dealmakers
  • 2.4. Targeted Drug Delivery partnering by deal type
  • 2.5. Targeted Drug Delivery partnering by therapy area
  • 2.6. Deal terms for Targeted Drug Delivery partnering
  • 2.6.1 Targeted Drug Delivery partnering headline values
  • 2.6.2 Targeted Drug Delivery deal upfront payments7
  • 2.6.3 Targeted Drug Delivery deal milestone payments
  • 2.6.4 Targeted Drug Delivery royalty rates

Chapter 3 - Leading Targeted Drug Delivery deals

  • 3.1. Introduction
  • 3.2. Top Targeted Drug Delivery deals by value

Chapter 4 - Most active Targeted Drug Delivery dealmakers

  • 4.1. Introduction
  • 4.2. Most active Targeted Drug Delivery dealmakers
  • 4.3. Most active Targeted Drug Delivery partnering company profiles

Chapter 5 - Targeted Drug Delivery contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Targeted Drug Delivery contracts dealmaking directory

Chapter 6 - Targeted Drug Delivery dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Targeted Drug Delivery deals by company A-Z

Appendix 2 - Targeted Drug Delivery deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - Targeted Drug Delivery deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty

Appendix 4 - Targeted Drug Delivery deals by therapy area

Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Targeted Drug Delivery partnering since 2010
  • Figure 2: Active Targeted Drug Delivery dealmaking activity- 2010 to 2016
  • Figure 3: Targeted Drug Delivery partnering by deal type since 2010
  • Figure 4: Targeted Drug Delivery partnering by disease type since 2010
  • Figure 5: Targeted Drug Delivery deals with a headline value
  • Figure 6: Targeted Drug Delivery deals with an upfront value
  • Figure 7: Targeted Drug Delivery deals with a milestone value
  • Figure 8: Targeted Drug Delivery deals with a royalty rate value
  • Figure 9: Top Targeted Drug Delivery deals by value since 2010
  • Figure 10: Most active Targeted Drug Delivery dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top